View source for Acute promyelocytic leukaemia (APL)

{{ICD10 transition status
| OldDxArticle =
| CurrentStatus = reconciled
| InitialEditorAssigned = Debbie Page-Newton
}}
{{ICD10 dx
| MinimumCombinedCodes =
| ICD10 Code=C92.4
| BugRequired= 
}}
{{ICD10 category|Heme/immunology}}{{ICD10 category|Neoplastic}}{{ICD10 category|Leukemia}} 

== Additional Info ==
*Acute promyelocytic leukemia (APML, APL) is a subtype of acute myeloid leukemia (AML), a cancer of the white blood cells. 
*In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes. The disease is characterized by a chromosomal translocation involving the retinoic acid receptor alpha (RARα or RARA) gene and is distinguished from other forms of AML by its responsiveness to all-trans retinoic acid (ATRA; also known as tretinoin) therapy. 
*Acute promyelocytic leukemia was first characterized in 1957 by French and Norwegian physicians as a hyperacute fatal illness, with a median survival time of less than a week. Today, prognoses have drastically improved; 10-year survival rates are estimated to be approximately 77% according to one study

{{ICD10 Guideline leukemia vs lymphoma}}

{{ICD10 Guideline Cancer}}

== Alternate ICD10s to consider coding instead or in addition ==
{{ListICD10Category | categoryName = Leukemia}}

== Candidate [[Combined ICD10 codes]] ==

== Related CCI Codes ==

{{Data Integrity Check List}}

== Related Articles ==
{{Related Articles}}


{{ICD10 footer}}
{{EndPlaceHolder}}